ZIM
WST icon

Zacks Investment Management’s West Pharmaceutical WST Stock Holding History

Zacks Investment Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Sell
823
-64
-7% -$19.6K ﹤0.01% 593
2026
Q1 		$222K Buy
+887
New +$221K ﹤0.01% 648
2024
Q2 		– Sell
-782
Closed -$310K – 724
2024
Q1 		$310K Sell
782
-8,288
-91% -$3.07M ﹤0.01% 529
2023
Q4 		$3.19M Sell
9,070
-19,701
-68% -$6.97M 0.04% 237
2023
Q3 		$10.8M Buy
28,771
+645
+2% +$249K 0.14% 141
2023
Q2 		$10.8M Buy
+28,126
New +$10M 0.14% 137
2023
Q1 		– Sell
-20,228
Closed -$71.2K – 709
2022
Q4 		$71.2K Buy
+20,228
New +$4.79M ﹤0.01% 582
2022
Q3 		– Sell
-11,476
Closed -$3.47M – 663
2022
Q2 		$3.47M Sell
11,476
-123
-1% -$40K 0.05% 198
2022
Q1 		$4.76M Sell
11,599
-14,620
-56% -$5.72M 0.07% 192
2021
Q4 		$12.3M Buy
26,219
+1,223
+5% +$526K 0.17% 130
2021
Q3 		$10.6M Buy
24,996
+1,337
+6% +$564K 0.17% 131
2021
Q2 		$8.5M Buy
23,659
+1,122
+5% +$371K 0.14% 140
2021
Q1 		$6.35M Sell
22,537
-4,682
-17% -$1.34M 0.11% 156
2020
Q4 		$7.71M Buy
27,219
+1,393
+5% +$391K 0.14% 132
2020
Q3 		$7.1M Buy
25,826
+6,984
+37% +$1.85M 0.14% 126
2020
Q2 		$4.28M Buy
+18,842
New +$3.7M 0.09% 145
2019
Q4 		– Sell
-3,357
Closed -$476K – 600
2019
Q3 		$476K Buy
+3,357
New +$462K 0.01% 445
2016
Q4 		– Sell
-2,748
Closed -$205K – 747
2016
Q3 		$205K Sell
2,748
-2,811
-51% -$223K 0.01% 598
2016
Q2 		$422K Buy
+5,559
New +$405K 0.01% 460
2014
Q4 		– Sell
-25,826
Closed -$1.16M – 761
2014
Q3 		$1.16M Buy
25,826
+1,375
+6% +$58.4K 0.04% 224
2014
Q2 		$1.03M Sell
24,451
-450
-2% -$19.3K 0.04% 252
2014
Q1 		$1.1M Sell
24,901
-4,639
-16% -$218K 0.04% 234
2013
Q4 		$1.45M Sell
29,540
-708
-2% -$33.1K 0.06% 199
2013
Q3 		$1.25M Sell
30,248
-2,942
-9% -$112K 0.05% 211
2013
Q2 		$1.17M Buy
+33,190
New +$1.09M 0.05% 205

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Zacks Investment Management's WST Position: Q2 2026 in Review

Zacks Investment Management reduced its West Pharmaceutical (WST) stake by 7.2% in Q2 2026, selling an estimated $19.6K and leaving 823 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #593.

Zacks Investment Management first reported a position in WST in Q2 2013 and has held it in 25 quarters since. The position peaked at $12.3M in Q4 2021. 832 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Zacks Investment Management held 823 shares of West Pharmaceutical worth $296K as of Q2 2026.
  • Zacks Investment Management sold 64 West Pharmaceutical shares in Q2 2026, an estimated $19.6K.
  • West Pharmaceutical made up ﹤0.01% of Zacks Investment Management's portfolio in Q2 2026, its #593 holding.
  • Zacks Investment Management first reported a position in West Pharmaceutical in Q2 2013 and has held it in 25 quarters since.
  • Zacks Investment Management's West Pharmaceutical position peaked at $12.3M in Q4 2021.
  • 832 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.